Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62,650,155
-
Total 13F shares
-
48,621,395
-
Share change
-
+1,049,294
-
Total reported value
-
$7,610,500,125
-
Put/Call ratio
-
98%
-
Price per share
-
$156.53
-
Number of holders
-
265
-
Value change
-
+$162,362,469
-
Number of buys
-
156
-
Number of sells
-
100
Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q2 2018
As of 30 Jun 2018,
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) was held by
265 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,621,395 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, FMR LLC, VANGUARD GROUP INC, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, OppenheimerFunds, Inc., Bank of New York Mellon Corp, BB BIOTECH AG, STATE STREET CORP, and JPMORGAN CHASE & CO.
This page lists
265
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.